A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects. Participants will take FX-111 every day by mouth and will

Trial Details

NCT ID
NCT07719361
Phase
PHASE1
Sponsor
Flare Therapeutics Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • FX-111
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • East Brunswick, New Jersey, United States|40.42788,-74.41598

Key Eligibility Criteria

  • Confirmed adenocarcinoma of the prostate.
  • PSA levels ≥ 2 ng/mL at screening visit.
  • Progressing PSA, defined as two consecutive increases in the most recent PSA measurements taken at least 1 week apart.
  • Progressed on Androgen Deprivation Therapy (ADT) and at least one prior potent Androgen Receptor (AR) pathway inhibitor given in castration-sensiti…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →